Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05794516 | A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants | PHASE1 | COMPLETED | 40 | — | — | Jun 19, 2023 | Mar 21, 2024 | Apr 13, 2025 | 1 | New Zealand |
| Arm | Type | Description |
|---|---|---|
| ZB004 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ZB004 | DRUG | ZB004 single doses administered subcutaneously as solution |
| Placebo | DRUG | Placebo single doses administered subcutaneously as solution |
Inclusion Criteria: * Healthy male or female participants 18 to 55 years of age. * Body weight ≥ 50 kg for male participants and ≥ 45 kg for female participants; body mass index of 18 to 35 kg/m\^2 for both male and female participants. * Considered in good health as determined by the Investigator....